PMID- 15231572
OWN - NLM
STAT- MEDLINE
DCOM- 20041123
LR  - 20220317
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 104
IP  - 8
DP  - 2004 Oct 15
TI  - Manipulating dendritic cell biology for the active immunotherapy of cancer.
PG  - 2235-46
AB  - Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) that have 
      an unequaled capacity to initiate primary immune responses, including tolerogenic 
      responses. Because of the importance of DCs in the induction and control of 
      immunity, an understanding of their biology is central to the development of 
      potent immunotherapies for cancer, chronic infections, autoimmune disease, and 
      induction of transplantation tolerance. This review discusses recent advances in 
      DC research and the application of this knowledge toward new strategies for the 
      clinical manipulation of DCs for cancer immunotherapy.
FAU - O'Neill, David W
AU  - O'Neill DW
AD  - New York University School of Medicine, 550 1st Ave, MSB 507, New York, NY 10016, 
      USA.
FAU - Adams, Sylvia
AU  - Adams S
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
LA  - eng
GR  - CA-84512/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
DEP - 20040701
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Vaccines)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/cytology/*immunology/metabolism
MH  - Humans
MH  - Immune Tolerance
MH  - *Immunotherapy, Active
MH  - Neoplasms/*immunology/*therapy
MH  - Vaccines/immunology
RF  - 159
EDAT- 2004/07/03 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/07/03 05:00
PHST- 2004/07/03 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/07/03 05:00 [entrez]
AID - S0006-4971(20)43279-3 [pii]
AID - 10.1182/blood-2003-12-4392 [doi]
PST - ppublish
SO  - Blood. 2004 Oct 15;104(8):2235-46. doi: 10.1182/blood-2003-12-4392. Epub 2004 Jul 
      1.